Skip to main content

CORRECTION article

Front. Med., 01 November 2023
Sec. Nuclear Medicine
Volume 10 - 2023 | https://doi.org/10.3389/fmed.2023.1324108

Corrigendum: Standardized classification schemes in reporting oncologic PET/CT

This article is a correction to:

  1. Standardized classification schemes in reporting oncologic PET/CT

    1. Read original article
\r\nVanessa Murad,Vanessa Murad1,2Roshini Kulanthaivelu,Roshini Kulanthaivelu1,2Claudia Ortega,Claudia Ortega1,2Patrick Veit-Haibach,Patrick Veit-Haibach1,2Ur Metser, Ur Metser1,2*
  • 1Molecular Imaging Division, Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital and Women's College Hospital, University of Toronto, Toronto, ON, Canada
  • 2University Medical Imaging Toronto, University of Toronto, Toronto, ON, Canada

A corrigendum on
Standardized classification schemes in reporting oncologic PET/CT

by Murad, V., Kulanthaivelu, R., Ortega, C., Veit-Haibach, P., and Metser, U. (2023). Front. Med. 9:1051309. doi: 10.3389/fmed.2022.1051309

In the published article, there was an error regarding the definition of disease progression according to PERCIMT criteria.

A correction has been made to 2. Reporting schemes and classifications, 2.1. Therapy response assessment with 18F-FDG PET, 2.1.4. PET Response Evaluation Criteria for Immunotherapy (PERCIMT), paragraph 2.

This sentence previously stated:

“Disease progression is determined in the following 3 scenarios: (1) when there are 4 or more new lesions measuring less than 10 mm in their functional diameter, (2) when there are 3 or more new lesions also with functional diameter below 10 mm, or (3) when there are 2 or more new lesions with a functional diameter greater than 15 mm.”

The corrected sentence appears below:

“Disease progression is determined in the following 3 scenarios: (1) when there are 4 or more new lesions measuring less than 10 mm in their functional diameter, (2) when there are 3 or more new lesions with functional diameter greater than 10 mm, or (3) when there are 2 or more new lesions with a functional diameter greater than 15 mm.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: PET, Deauville, Krenning, PROMISE, immunotherapy, head and neck cancer

Citation: Murad V, Kulanthaivelu R, Ortega C, Veit-Haibach P and Metser U (2023) Corrigendum: Standardized classification schemes in reporting oncologic PET/CT. Front. Med. 10:1324108. doi: 10.3389/fmed.2023.1324108

Received: 19 October 2023; Accepted: 20 October 2023;
Published: 01 November 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Murad, Kulanthaivelu, Ortega, Veit-Haibach and Metser. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Ur Metser, Ur.metser@uhn.ca

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.